Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962895 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
A Phase 2 study of Primary Sjogren Syndrome, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT02962895 is a Phase 2 study of Primary Sjogren Syndrome that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 190 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT02962895, a Phase 2 study of Primary Sjogren Syndrome, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VAY736
Study Locations (20)
Other
- Novartis Investigative Site - CABA
- Novartis Investigative Site - Córdoba
- Novartis Investigative Site - Córdoba
- Novartis Investigative Site - Graz
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Santiago
- Novartis Investigative Site - Santiago
- Novartis Investigative Site - Brest
- Novartis Investigative Site - Lille
Pennsylvania
- UPMC - Pittsburgh
- Advanced Rheumatology and Arthritis Wellness Center - Wexford
Texas
- Baylor College Of Medicine - Houston
- First Outpatient Research Unit - San Antonio
Florida
- Integral Rheumatology and Immunology Specialists IRIS - Plantation
Indiana
- Indiana Univ School of Dentistry - Indianapolis
Maryland
- The John Hopkins Jerome L Greene Sjogren - Baltimore
Massachusetts
- Tufts School of Dental Medicine - Boston
New York
- AAIR Research Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2021-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02962895
The ClinicalTrials.gov registry entry for NCT02962895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sjogren Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02962895 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT02962895 about?
NCT02962895 is a clinical study titled "Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)". The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
What is the current status of trial NCT02962895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2017-06-27. Estimated completion is 2021-09-23.
What conditions does trial NCT02962895 study?
This clinical trial studies the following conditions: Primary Sjogren Syndrome.
What interventions are being tested in trial NCT02962895?
The interventions under investigation include: Placebo (OTHER), VAY736 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02962895?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02962895 being conducted?
This trial has 20 study locations across Florida, Indiana, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.